Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma
Chen J, Lenihan D, Phillips S, Jagasia M, Goodman S, Kassim A, Lacy S, McDonagh K, Moslehi J, Sethi T, Slosky D, Ukaegbu O, Cornell R. Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma. Blood 2015, 126: 5363. DOI: 10.1182/blood.v126.23.5363.5363.Peer-Reviewed Original ResearchCardiac adverse eventsIndependent risk factorCardiac eventsCumulative incidenceRisk factorsMultiple myelomaPrior historyAdverse eventsAntithrombotic therapyPI therapyMedian durationPrior linesMore patientsMale genderAtherosclerotic cardiovascular disease riskC groupCardiac Toxicity AssociatedMedian prior linesLipid-lowering medicationsB groupCardiovascular disease riskStem cell transplantationCourse of treatmentProteasome inhibitor bortezomibIncidence of PI